Aigen Investment Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-37,674
Closed -$475K – 514
2025
Q4
$475K Buy
37,674
+27,443
+268% +$314K 0.11% 254
2025
Q3
$102K Buy
+10,231
New +$91.8K 0.02% 737
2025
Q2
– Sell
-15,066
Closed -$126K – 773
2025
Q1
$126K Buy
+15,066
New +$126K 0.02% 673
2024
Q4
– Sell
-25,591
Closed -$213K – 717
2024
Q3
$213K Buy
+25,591
New +$200K 0.04% 569
2023
Q4
– Sell
-27,905
Closed -$118K – 777
2023
Q3
$118K Buy
+27,905
New +$104K 0.02% 734
2021
Q2
– Sell
-33,210
Closed -$224K – 452
2021
Q1
$224K Buy
+33,210
New +$184K 0.03% 506

Other funds holding AMRX

Aigen Investment Management's AMRX Position: Q1 2026 in Review

Aigen Investment Management sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 37,674 shares — an estimated $475K sold.

Aigen Investment Management first reported a position in AMRX in Q1 2021 and held it in 6 quarters. The position peaked at $475K in Q4 2025. 317 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Aigen Investment Management reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Aigen Investment Management sold 37,674 Amneal Pharmaceuticals shares in Q1 2026, an estimated $475K.
  • Aigen Investment Management first reported a position in Amneal Pharmaceuticals in Q1 2021 and held it in 6 quarters.
  • Aigen Investment Management's Amneal Pharmaceuticals position peaked at $475K in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Aigen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.